BioNTech And Pfizer To Begin Clinical Trial For Covid-19 Vaccine

MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. BioNTech and U.S. pharmaceutical giant Pfizer announced today that German authorities have granted them approval to begin clinical trials for BioNTech's BNT162, a possible vaccine against Covid-19. BioNTech will conduct the trial in Germany with 200 participants while Pfizer will conduct its trial in the United States once regulatory authorities grant the trial there. (Photo by Thomas Lohnes/Getty Images)
MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. BioNTech and U.S. pharmaceutical giant Pfizer announced today that German authorities have granted them approval to begin clinical trials for BioNTech's BNT162, a possible vaccine against Covid-19. BioNTech will conduct the trial in Germany with 200 participants while Pfizer will conduct its trial in the United States once regulatory authorities grant the trial there. (Photo by Thomas Lohnes/Getty Images)
BioNTech And Pfizer To Begin Clinical Trial For Covid-19 Vaccine
購買授權
我可如何使用此圖片？
HK$3,500.00
HKD

詳情

限制條件：
關於所有商業或推廣用途，請聯絡您當地辦公室的業務代表。
來源:
Thomas Lohnes / 特約
編輯性內容編號：
1220435202
圖像集:
Getty Images News
建立日期：
2020年04月22日
上傳日期：
授權類型：
權利管理
發佈資訊:
無許可授權 更多資料
來源：
Getty Images Europe
物件名稱：
_dsc0529_lohnes_20200422105137798.jpg
最大檔案大小：
8256 x 5504 像素 (69.90 x 46.60 cm) - 300 dpi - 8 MB